ClinicalTrials.gg
RecruitingNCT07160634Updated Nov 20, 2026

A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)

A Phase 3 interventional study of SGT-003 and Placebo in Duchenne Muscular Dystrophy, sponsored by Solid Biosciences Inc.. Recruiting at 13 sites in 6 countries. Open to male participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Solid Biosciences Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 20, 2026First sites in Netherlands, Spain and United Kingdom6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
7 Years to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 66 studies in Muscular Dystrophy, Duchenne with a site in Canada — 6 open to participants now, 15 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · Canada.

Planned enrollment
26th of 62
80 · median 68
Started
2025
with 1 other
Phase 3
26 of 66
3 open now
Primary completion
2029-01
later than 9 of 14 live
Registered
63rd of 66
by date

Among the 66 studies in Muscular Dystrophy, Duchenne with a site in Canada, this one is the 26th largest by planned enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 9 of the 14 other live ones, and was the 63rd registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

6 of the 66 studies in Muscular Dystrophy, Duchenne with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Muscular Dystrophy, Duchenne with a site in Canada, or all of them as a file.
02

Study summary

This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD. The secondary objectives include the evaluation of additional efficacy and safety outcomes. The study will be divided into 2 parts. Participants will be randomized 1:1 to either SGT-003 in Part 1 followed by placebo in Part 2 or to placebo in Part 1 followed by SGT-003 in Part 2. Participants will continue to be monitored in long term follow up (LTFU) for at least 5 years from their SGT-003 dosing date.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • SGT-003
  • Duchenne Muscular Dystrophy (DMD)
  • adeno-associated virus (AAV)
  • IMPACT DUCHENNE
04

Who can participate

Ages eligible
7 Years to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is ambulatory.
  • Established clinical diagnosis of DMD and documented DMD gene mutation predictive of DMD phenotype.
  • Negative for antibodies against adeno-associated virus serotype 9 (AAV9).
  • On a stable daily oral regimen of at least 0.5 mg/kg/day prednisone or 0.75 milligrams per kilogram per day (mg/kg/day) deflazacort for at least 6 months prior to entering the study, allowing for weight-based dose modifications in accordance with clinical practice.
  • Meet 10-meter walk/run time criteria.
  • Meet time to rise from supine criteria.
  • Participant has bodyweight ≤50 kg.

Exclusion criteria

Exclusion Criteria:

  • Current or prior treatment with an approved or gene transfer drug or gene editing therapy.
  • Exposure to vamorolone, givinostat, approved or investigational dystrophin- or disease-modifying drugs (such as eteplirsen, golodirsen, casimersen, viltolarsen, and ataluren), or another investigational drug for any indication within 6 months or 5 half-lives, whichever is longer, prior to enrollment.
  • Established clinical diagnosis of DMD that is associated with any deletion variant or variant predicted not to express exons 1 to 11, exons 42 to 45, or exons 57 to 69, inclusive of the DMD gene as documented by a genetic report.

Other Inclusion/Exclusion criteria to be applied as per protocol.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    SGT-003 in Part 1, Placebo in Part 2

    Enrolled participants will receive a single intravenous (IV) infusion of SGT-003 in Part 1 and may receive a single IV infusion of matching Placebo in Part 2 per protocol-defined eligibility criteria.

    Drug: SGT-003 · Drug: Placebo

  • Experimental
    Placebo in Part 1, SGT-003 in Part 2

    Enrolled participants will receive a single intravenous (IV) infusion of matching Placebo in Part 1 and a single IV infusion of SGT-003 in Part 2 per protocol-defined eligibility criteria.

    Drug: SGT-003 · Drug: Placebo

Interventions

  • DrugSGT-003

    Adeno-associated virus (AAV)-based gene therapy that delivers a codon-optimized and CpG island-minimized human 5-repeat microdystrophin (h-μD5)

  • DrugPlacebo

    IV infusion

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Time to Rise (TTR) from Supine Velocity (rise/s) at Day 540

    Time frame: Baseline, Day 540

Secondary outcomes

  1. Change From Baseline in Stride Velocity 95th Centile (SV95C) (m/s) at Day 540

    Time frame: Baseline, Day 540

  2. Change From Baseline in 4-Stair Climb (4SC) Velocity (Tasks/s) at Day 540

    Time frame: Baseline, Day 540

  3. Change From Baseline in North Star Ambulatory Assessment (NSAA) total score at Day 540

    Time frame: Baseline, Day 540

  4. Change From Baseline in 10-meter Walk/Run (10MWR) Velocity (m/s) at Day 540

    Time frame: Baseline, Day 540

  5. Cumulative Loss of Function in NSAA Items at Day 540

    Time frame: At Day 540

  6. Change from Baseline in Percent Predicted Forced Vital Capacity (FVC) at Day 540

    Time frame: Baseline, Day 540

  7. Change from Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Day 540

    Time frame: Baseline, Day 540

  8. Change from Baseline in Percent Predicted Forced Expiratory Volume in 1 second (FEV1) at Day 540

    Time frame: Baseline, Day 540

  9. Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at Day 540[

    Time frame: Baseline, Day 540

  10. Change from Baseline in Global Longitudinal Strain (GLS) at Day 540

    Time frame: Baseline, Day 540

  11. Change from Baseline in the Pediatric Outcomes Data Collection Instrument (PODCI) Global score at Day 540

    Time frame: Baseline, Day 540

  12. Number of Participants with Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of special interest (AESIs), and clinically significant changes in Electrocardiogram (ECG) and Echocardiography (ECHO)

    Time frame: From first dose up to Day 540

  13. Change From Baseline in Viral Shedding as Measured by Polymerase Chain Reaction (PCR) at Day 360

    Time frame: Baseline, Day 360

  14. Change From Baseline in Anti-Adeno-Associated Virus (AAV) Antibody Titers at Day 540

    Time frame: Baseline, Day 540

  15. Change from Baseline in Microdystrophin T-cell Reactivity by Enzyme-Linked Immunospot at Day 540

    Time frame: Baseline, Day 540

07

Study locations

10 of 13 sites recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
    Not yet recruiting
  • Neurology Rare Disease Center
    Flower Mound, Texas 75082, United States
    Not yet recruiting
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23510, United States
    Not yet recruiting
  • The Children's Hospital of Westmead
    Sydney, New South Wales, Australia
    Recruiting
  • Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
    Recruiting
    • Israt Yasmeen · ContactIsrat.Yasmeen@ahs.ca · 587-943-0851
    • Jean Mah, MD · Principal investigator
  • BC Children's Hospital
    Vancouver, British Columbia, Canada
    Recruiting
    • Nela Martic · Contactnmartic3@cw.bc.ca · 604-875-2345
    • Kathryn Selby, MD · Principal investigator
  • Children's Hospital of Eastern Ontario (CHEO)
    Ottawa, Ontario, Canada
    Recruiting
    • Emilie Hill-Smith · Contactehillsmith@cheo.on.ca · 613-737-7600
    • Dr. Hugh McMillan, MD, MSc, FRCPC, FAA · Principal investigator
  • The Hospital for Sick Children (SickKids)
    Toronto, Ontario, Canada
    Recruiting
  • Leids Universitair Medisch Centrum (LUMC)
    Leiden, South Holland, Netherlands
    Recruiting
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Barcelona, Spain
    Recruiting
    • Andrés Nascimento, PhD, MD · Principal investigator
  • Hospital: Hospital Universitario y Politecnico La Fe
    Valencia, Spain
    Recruiting
    • Nuria Muelas Gómez, PhD, MD · Principal investigator
  • Oxford University Hospitals NHS Trust - John Radcliffe Hospital - Children's Hospital Oxford
    Oxford, Oxfordshire, United Kingdom
    Recruiting
    • Laurent Servais · Principal investigator
  • Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals Foundation Trust
    Newcastle upon Tyne, Tyne and Wear, United Kingdom
    Recruiting
    • Michela Guglieri, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2029, 39 months after the start.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 8, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2034
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first sites in Netherlands, Spain and United Kingdom
Show 6 added (2 Spain, 2 United Kingdom, 1 Canada, 1 Netherlands)
  • Children's Hospital of Eastern Ontario (CHEO) · Ottawa, Canada
  • Leids Universitair Medisch Centrum (LUMC) · Leiden, Netherlands
  • Hospital Sant Joan de Deu · Esplugues de Llobregat, Spain
  • Hospital: Hospital Universitario y Politecnico La Fe · Valencia, Spain
  • Oxford University Hospitals NHS Trust - John Radcliffe Hospital - Children's Hospital Oxford · Oxford, United Kingdom
  • Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals Foundation Trust · Newcastle upon Tyne, United Kingdom
Nov 20, 2026
Show all 2 updates
  1. Nov 20, 2026
    6 sites added — first sites in Netherlands, Spain and United Kingdom
    Show 6 added (2 Spain, 2 United Kingdom, 1 Canada, 1 Netherlands)
    • Children's Hospital of Eastern Ontario (CHEO) · Ottawa, Canada
    • Leids Universitair Medisch Centrum (LUMC) · Leiden, Netherlands
    • Hospital Sant Joan de Deu · Esplugues de Llobregat, Spain
    • Hospital: Hospital Universitario y Politecnico La Fe · Valencia, Spain
    • Oxford University Hospitals NHS Trust - John Radcliffe Hospital - Children's Hospital Oxford · Oxford, United Kingdom
    • Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals Foundation Trust · Newcastle upon Tyne, United Kingdom
    + 2 other changes: identifiers and verification date
  2. Sep 28, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07160634
Lead sponsor
Solid Biosciences Inc.
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Oct 22, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jan 2034 (estimated)
Last update
Nov 20, 2026

Study contacts

Solid Bio Clinical Trials
Contact
clinicaltrials@solidbio.com
6173374680

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion